-

a2z Radiology AI Expands Acute Care Suite with Third FDA-Cleared Device

New FDA clearance brings a2z’s abdomen-pelvis CT triage portfolio to 26 findings across three devices.

BOSTON--(BUSINESS WIRE)--a2z Radiology AI Inc. today announced FDA clearance of a2z-Omni-Triage, its third FDA-cleared device for triage and notification on abdomen-pelvis CT.

a2z-Omni-Triage flags suspected cases of nine findings: moderate or large layering pleural effusion, pneumothorax, complex pleural collection, bowel perforation, moderate or severe hydronephrosis, large aortic aneurysm (5 cm or larger), non-sacral pelvic fracture, sacral or coccygeal fracture and soft tissue abscess. It joins a2z-Unified-Triage, cleared for seven findings, and a2z-Abdo-Triage, cleared for ten. Each device’s findings were cleared with their own definitions and performance testing.

“A CT scan ordered for abdominal pain shows far more than the abdomen, from the base of the lungs to the bones of the pelvis,” said Samir Rajpurkar, co-founder and CEO of a2z Radiology AI. “a2z-Omni-Triage can flag nine findings across that range for the care team.”

“On a busy shift with a long worklist, even a CT ordered as routine can turn out to need urgent attention,” said Michael Moritz, MD, CIIP, Chief Medical Information Officer of a2z Radiology AI. “a2z-Omni-Triage helps bring those studies with suspected findings forward for review.”

“A scan isn’t read one finding at a time, and the software that supports clinicians shouldn’t stop at one either,” said Pranav Rajpurkar, PhD, co-founder of a2z Radiology AI and Associate Professor of Biomedical Informatics at Harvard Medical School.

a2z-Omni-Triage analyzes abdominopelvic CT images acquired with or without intravenous contrast in adults aged 22 and older. It works in parallel with standard-of-care image interpretation, and notified clinicians remain responsible for viewing the full images. Findings involving the chest apply only when that anatomy is included in the images analyzed.

About a2z Radiology AI

a2z Radiology AI builds AI to support care teams in acute care imaging, starting with abdomen-pelvis CT. The name a2z reflects its founding ambition to support comprehensive medical image interpretation, from A to Z.

The company was co-founded by Pranav Rajpurkar, an Associate Professor of Biomedical Informatics at Harvard Medical School, and Samir Rajpurkar, a technology entrepreneur. a2z is backed by Khosla Ventures and SeaX Ventures.

For more information, visit a2zradiology.ai.

Contacts

Media contact: a2z Radiology AI, info@a2zradiology.ai

a2z Radiology AI Inc.


Release Summary
New FDA clearance brings a2z's abdomen-pelvis CT triage portfolio to 26 findings across three devices.
Release Versions

Contacts

Media contact: a2z Radiology AI, info@a2zradiology.ai

More News From a2z Radiology AI Inc.

a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT

BOSTON--(BUSINESS WIRE)--a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT...

a2z Radiology AI Expands Acute Care Suite with 10 Newly Cleared Findings

BOSTON--(BUSINESS WIRE)--a2z Radiology AI receives FDA clearance for 10 findings, expanding its abdomen-pelvis CT triage portfolio to 17 findings across two devices....

a2z Radiology AI Introduces First Multi-Condition Triage for Abdomen-Pelvis CT

BOSTON--(BUSINESS WIRE)--a2z Radiology AI has received U.S. FDA clearance for a2z-Unified-Triage, a single device that flags and prioritizes seven urgent findings on abdomen-pelvis CT scans simultaneously. With RSNA 2025, radiology's largest annual conference, just days away, a2z is positioning itself as a leader in abdomen-pelvis AI. The company is bringing a first-of-its-kind capability to the U.S. market: a single system that triages seven urgent conditions on abdomen-pelvis CTs in one pass....
Back to Newsroom